Treating Hypercholesterolemia in Older Adults for Primary Prevention of Cardiovascular Events.

Al-Ani, Awsse; Jamil, Yasser; Orkaby, Ariela R.

As the population ages, the demographic of adults aged 75 years and older in the U.S. is projected to grow to 45 million by 2050. Hypercholesterolemia is directly linked to atherosclerotic cardiovascular disease (ASCVD), which remains the leading cause of death in older adults. However, primary prevention of ASCVD through lipid-lowering agents remains unclear among older adults owing to limited involvement of older adults in current trials, lack of dedicated trials, and evidence primarily derived from secondary and retrospective analyses. Therefore, this article aims to (1) review key updates from the latest guidelines on treatment of hypercholesterolemia in older adults, (2) highlight limitations of the current ASCVD risk scores in the geriatric population, (3) present outcomes from key studies on the use of lipid-lowering agents and associated side effects, including a brief review of novel agents such as bempedoic acid, although very few adults over age 75 were included in these trial, and (4) finally, highlight upcoming dedicated trials of statins in older adults for the primary prevention of important geriatric outcomes as well as ASCVD.

CARDIOVASCULAR disease prevention; HYPERCHOLESTEREMIA treatment; MEDICAL protocols; PATIENT education; ANTILIPEMIC agents; EXERCISE; INVESTIGATIONAL drugs; CLINICAL trials; CARDIOVASCULAR diseases risk factors; DECISION making; POLYPHARMACY; PATIENT-centered care; EZETIMIBE; DRUG efficacy; STATINS (Cardiovascular agents); GERIATRIC assessment; SOCIAL support; PREVENTIVE health services; DIET; OLD age

Drugs & Aging, 2024, Vol 41, Issue 9, p699

1170-229X

Academic Journal

10.1007/s40266-024-01139-4